Black men with advanced prostate cancer have a greater chance of survival after immunotherapy treatment, according to a Duke Cancer Institute study.

While several immunotherapy treatments for multiple myeloma and other hematologic cancers are now standard of care, Provenge, which was FDA approved in 2010, was the first immunotherapy treatment for prostate cancer. Today, there are other promising prostate cancer immunotherapy clinical trials underway, and Black patients could be big beneficiaries. However, participation in these clinical trials is imperative to understanding and realizing these potential benefits.

Only 30 Black patients participated in the Provenge clinical trial, and it took seven years after it was approved to understand the benefits for this population fully. With Black men suffering a prostate cancer death rate more than twice that of all other men, delays in realizing the benefits of new immunotherapies mustn't be repeated.

Immunotherapy has the potential to reshape prostate cancer treatment by helping the body heal itself without the side effects of hormone and chemotherapy treatments.



XALute (pronounced salute) is an immunotherapy clinical trial that is currently recruiting patients with advanced prostate cancer (cancer has spread to other parts of the body)

Act Now to See if You Qualify!

>> Visit the Amgen Pre-Screener or scan the QR Code to see if you qualify.

>> For more information, read the Patient Summary.

Omaha - 003

The Omaha-003 clinical trial is for participants who have metastatic castration-resistant prostate cancer that failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer.

Omaha - 004

The Omaha-004 clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and whose cancer progressed on or after they were previously treated with next-generation Hormonal Agent (NHA).

MK-5684-01A

This clinical trial aims to test the safety and effectiveness of an investigational drug called MK-5684 (a pill taken by mouth) to see if it may help stop or slow the spread of prostate cancer for metastatic castration-resistant prostate cancer (mCRPC) patients.